

## DyeVert Plus Featured at the Society for Cardiovascular Angiography and Interventions 2018 Scientific Session

**April 30, 2018- Minnesota, United States and Melbourne, Australia** – Osprey Medical (ASX: OSP) today released highlights of its prominent presentations at the Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions, a premier event attended by nearly 2,000 interventional cardiology and cardiovascular professionals, occurring April 25 – 28, 2018 in San Diego, California.

Results from the study titled *“A Multi-Center Observational Study of the DyeVert Plus™ Contrast Reduction System”* was presented during a featured “Best of Best” poster presentation by Dr. Kretton Mavromatis on behalf of the DyeVert Plus Study Investigators. Dr. Mavromatis is an Interventional Cardiologist at the Atlanta VA Medical Center/Emory University School of Medicine and was one of eight Principle Investigators on the DyeVert Plus Study. The study enrolled 114 poor kidney function patients undergoing imaging and possible treatment of blocked heart arteries. Use of the DyeVert Plus System resulted in a mean 40% contrast media (dye) volume reduction, which was statistically significant and clinically meaningful. Acute kidney injury (AKI), occurred in 11 patients, and only 3 events were attributed to contrast media.



Dr. Mavromatis commented: *“This study demonstrates the DyeVert Plus System is easy to use, substantially reduces mean contrast media volume 40%, and allows for real-time contrast threshold monitoring. The low occurrence of contrast-related adverse events in this study suggests a relationship between contrast media volume reduction and contrast-related adverse events.”*

Of the 370 abstracts accepted for the 2018 Scientific Sessions, the DyeVert Plus Study was one of six abstract winners chosen and announced on April 27th in a featured session at the conference. The DyeVert study abstract was published in parallel in the April issue of *Catheterization & Cardiovascular Interventions*.

Throughout the conference, several live case demonstrations were remotely broadcast from hospitals in the US and Europe. Dr. Emmanouil Brilakis, from the Minneapolis Heart Institute, provided a live complex case demonstration of a chronic total occlusion procedure that included the use of DyeVert Plus as a dye minimization strategy. Chronic total occlusion procedures involve treatment of one or more blocked coronary arteries in a highly complex procedure typically involving extended procedure times and large doses of contrast media.

President and CEO Mike McCormick commented: *“Osprey was pleased to partner with the DyeVert Plus Investigators on this important clinical study. The selection of the DyeVert Plus clinical trial as one of the top abstracts of the SCAI Scientific Sessions reflects the strong interest from physicians for technologies that assist in the reduction of contrast-induced acute kidney injury. The combination of the award winning abstract and live case with the DyeVert Plus system facilitate brisk traffic at our exhibit booth and will generate evaluations and new customers in the future.”*

**Contact details:****Media**

Amanda Loh  
Buchan Consulting  
T: (613) 8866 1210  
[aloh@buchanwe.com.au](mailto:aloh@buchanwe.com.au)

**Investors**

Rebecca Wilson  
Buchan Consulting  
M: (61) 417 382 391  
[rwilson@buchanwe.co.au](mailto:rwilson@buchanwe.co.au)

**Company**

Doug Schoenberg  
VP of Marketing  
T: (952) 955 8230  
[dschoenberg@ospreymed.com](mailto:dschoenberg@ospreymed.com)

**About Osprey**

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast Induced Acute Kidney Injury (AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ Plus System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

**Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

**Foreign Ownership Restriction**

Osprey's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.